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T olerogenicity 
Repopulation ofliver endothelium by 
bone-marrow-derived cells. Gao Z, McAllister 
VC, WiLliams GM. Lancet 2001;357:932-933. 
(Reprinted with permission from Elsevier 
Science [The Lancet, 2001, Vol 357, P 932].) 
Abstract 
The mechanism underlying the immunological advantage of 
hepatic allografts relative to other organs is incompletely 
understood. We used molecular probes for the repetitive 
units on the Y chromosome, to identifY an increasing num-
ber of male liver venous endothdial cells in needle biopsy 
samples of men who received female donor liver grafts. We 
have also shown repopulation of liver endothelium by bone 
marrow derived cells in a male to female mouse bone marrow 
transplant model. We conclude that the liver has unique 
venous endothelium characterized by turnover and 
replacement by bone marrow derived cells. 
Comments 
Gao et all have proposed that liver allografts acquire a 
survival advantage by the gradual replacement of their 
portal and central venous endothelial cells by recipient 
cells of bone marrow origin. The clinically based 
hypothesis, supported by studies of the rapid turnover 
and replacement of these cells in mouse radiation chi-
meras, is reminiscent of Woodruff's explanation more 
than 4 decades ago of allograft acceptance by " ... 
replacement of certain elements of graft, for example 
connective tissue stroma and vascular endothelium."2 
Several years later (in 1965), after the field of kidney 
transplantation had been launched with very little warn-
ing, Medawar was perplexed by the unexpected successes 
and wrote that" ... foreign kidneys do sometimes become 
acceptable to their hosts for a reason other than acquired 
tolerance in a technical sense ... One possible explanation 
is the progressive and perhaps very extensive replacement 
of the vascular endothelium of the graft by endothelium of 
host origin, a process that might occur insidiously and 
imperceptibly during a homograft reaction weakened by 
immunosuppressive drUgs."3 
In 1971, the senior author of the current Lancet 
report (G.M. Williams) published the first of a series of 
studies of allograft vasculature, beginning with a simple 
model of reendothelialization of free aortic allografts 
with or without recipient immunosuppression with 
6-mercaptopurine (6-MP).4 The endothelial replace-
ment occurred more rapidly and completely in the non-
treated animals in which rejection promptly destroyed 
the donor endothelium, bur the same repopulation by 
recipient cells occurred more slowly in immunosup-
pression-protected allografts and in radiation chimeras 
analogous to those in the mouse experiments of 200 1. 
Although the technology of 30 years ago'did not pro-
vide unequivocal evidence that the replacement cells 
were of bone marrow origin, this possibility was consid-
ered by the investigators. 4 
It is clear from the human and mouse studies of Gao 
et all that endothelium is, in fact, replaced in the venous 
system of the liver allograft. Studies of comparable arte-
rial changes were not described in their human liver 
graft specimens and were not seen in the arteries of the 
native parenchymal organs of mouse radiation chime-
ras. However, partial arterial endothelial replacement 
has been documented in a small number of kidney 
allografts after relatively short follow-ups5-7 and in 7 
related donor kidneys studied by Randhawa et alB that 
had fUnctioned for 26 to 29 years. The patchy areas of 
recipient vascular endothelium in these kidneys, and in 
the coronary arteries of cardiac allografts described by 
others,9.10 were thought by Randhawa et alB to have 
followed injury or rejection of the original donor cells 
with replacement by recipient mononuclear or endo-
thelial progenitor cells of bone marrow origin. How-
ever, the potentially adverse implications of reendothe-
lialization initiated by rejection or mechanical endothelial 
damage (eg, ischemia) do not apply with the natural turn-
over of endothelial cells in the liver venous system.! 
The changes in both the venous and arterial system of 
allografts are of considerable interest. As the authors imply, 
however, the possible graft survival advantage should not 
be equated with the "hepatic tolerogenicity" that was first 
recognized in 1962 with the observation that nonhepatic 
abdominal visceJ;al allografts in untreated dogs have a 
reduced severity of rejection if they are accompanied by 
the donor liver.!! By 1965, it was established that most 
canine liver recipients who survived for 4 months under 
azathioprine immunosuppression were tolerant (ie, no 
longer needed treatment to sustain graft survival). After 
noting that, " ... the frequency and rapidity with which 
dogs could be withdrawn from immunosuppression is 
remarkable. , .", it was added that, ", .. The consistency 
with which this state of host versus graft nonreactivity , .. 
seemed to develop exceeds that reported after canine renal 
homotransplantarions ... It also is important to note that 
cessation of therapy was not followed by a graft versus host 
reaction. "12 
The liver allograft was subsequently shown to self-
induce permanent tolerance without immunosuppres-
sion in at least 3 species: unpredictably in a signillcant 
minority of randomly paired outbred pigs,13-15 invari-
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ably with a small number of strain combinations of 
inbred rats,16,17 and in at least 50% of experiments in 
about 85% of all rested mousestrain pairings,18 The 
self-induced tolerance is antigen-specific: ie, extends to 
other donor tissues and organs,16-19 Although the 
induction of spontaneous tolerance has been widely 
construed to be a specific capability of the liver, donor-
specific tolerance can be induced in mice by heart l8,20 
and kidney allografts, 21 bur only with a small number of 
strain combinations, 
With the discovery in 1992 that 30 of 30 long-
surviving human recipients of livers and kidneys had 
low-level donor leukocyte microchimerism, it was real-
ized that organ engraftment was the product of a double 
immune reaction: ie, "" ,responses of co-existing 
donor and recipient cells, each to the other, causing 
reciprocal clonal exhaustion, followed by peripheral 
clonal deletion, "22.23 Although clonal exhaustion-dele-
tion had been postulated in 1969 as the seminal basis of 
organ tolerogenicity24 but dismissed as an unsubstan-
tiated theory, the existence and importance of 
clonal exhaustion-deletion has been established since 
1990.25•26 It also was concluded that the alternative 
explanations of organ allograft acceptance (recently 
summarRed by Bishop and McCaughan27) had, 
" ... defied attempts at verification, probably because 
the proposed elements of each theory are simply epi-
phenomena of the key event: leukocyte migration and 
repopulation [i.e. localization]. "22 
It was evident that the liver is the most tolerogenic 
organ because of its huge content of leukocytes.22•23 
Reciprocal modulation of the migratory immune com-
petent donor leukocytes and the host immunocytes 
explained why graft-versus-host disease was so uncom-
mon after clinical organ transplantation compared with 
the high risk of this complication in cytoablated recip-
ients of bone marrow cells or leukocyte-rich organs. 
How the small number of donor leukocytes that persist 
after the acute posttransplant cell migration maintain 
the clonal exhaustion-deletion achieved at the outset 
has been described elsewhere in detail. 28.29 The chimer-
ism-dependent deletional tolerance and its chimerism-
dependent maintenance are the crucial mechanisms for 
prolonged survival of any organ allograft including the 
liver. However, changes in the graft, such as the replace-
ment of vascular endothelium, may be significant 
adjunct mechanisms. 
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